

# Supreme Pharmaceuticals

10:43 23 Oct 2014

## Supreme to raise another \$1 mln for Kincardine medical marijuana facility

Supreme Pharmaceuticals (CSE:SL) says it will raise up to \$1.0 million via a non-brokered private placement financing, with the funds to be used for the continued development of its Kincardine medical marijuana facility.

The company will issue up to 3.12 million units at a price of 32 cents apiece. Every unit will be made up of one common share, and one half of a share purchase warrant, with each whole warrant entitling the holder to buy an additional share for 50 cents, for a period of two years from closing.

The offering is expected to close November 17.

The news comes on the heels of Supreme raising a total of \$2.6 million from a two-part financing earlier this month. The Vancouver, BC-based company will put all the money towards the development of its Kincardine medical marijuana facility, which is approaching the production phase.

Due to strong support from the local community, Supreme has been able to move quickly to implement its proposed plan to produce up to 24 million grams of medical marijuana, for which it received conditional pre-approval from Health Canada in January.

To move to post-license production status, the company has to adopt the high-level security measures required by Health Canada at the 342,000 square foot operation. Health Canada also has to perform a final inspection of the facility.

In September, Supreme said that it anticipates being ready for the pre-license inspection by Health Canada to verify its compliance with the requirements of the new MMPR (Marijuana for Medical Purposes Regulations) program in November.

Given the size of the facility, Supreme will bring on production gradually, tailoring output to meet the strain and volume demands of the market.

Late last month, Supreme also appointed start-up maven Chris Bechtel to its advisory board as the company gets ready to usher in a new development phase. Bechtel launched a small oil and gas business in Houston Texas in 1983 that was sold to in 2006 to Weatherford International, one of the largest global providers of oil and gas services.

Bechtel also has experience in the medical marijuana industry, after investigating the medical benefits of cannabis for an immediate family member. He has since become a private investor in over a half a dozen companies in the cannabis sector, as well as become a consultant and advisor to these businesses.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private

### Share Information

**Code:** SL

**Listing:** CNSX

**Sector:** Pharmaceuticals

**Website:**

[www.supremepharmaceuticals.com](http://www.supremepharmaceuticals.com)

### Company Synopsis:

*Supreme Pharmaceuticals Inc. is a Company that is dedicated to providing and developing an in-licensed technology with an IP portfolio aimed at targeting Obesity. The platform will address the fundamental changes in healthcare and enabling relief for millions people in Obesity. In addition, the company is also pursuing opportunities in the Medical Marijuana Industry.*

**Author:**

**Proactive Investors Ltd**

**+44 (0)207 989 0813**

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.